Sara Rushwan
Overview
Explore the profile of Sara Rushwan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shankar M, Charantimath U, Dandappanavar A, Hazfiarini A, Pujar Y, Somannavar M, et al.
BJOG
. 2025 Jan;
PMID: 39871821
Objective: To explore factors affecting participation of pregnant women in randomised clinical trials in Belagavi, Karnataka, India. Design: A qualitative study using semi-structured in-depth interviews and focus group discussions as...
2.
Shankar M, Gulmezoglu A, Vogel J, Goudar S, McDougall A, Somannavar M, et al.
Commun Med (Lond)
. 2024 Dec;
4(1):260.
PMID: 39643638
No abstract available.
3.
Rushwan S, Forna F, Abubeker F, Tufa T, Millogo T, Nakalembe M, et al.
Int J MCH AIDS
. 2024 Dec;
13(Suppl 1):S15-S27.
PMID: 39629311
Background And Objective: Globally, postpartum hemorrhage (PPH) remains the most common direct cause of maternal mortality. This study evaluated the feasibility and acceptability of introducing heat-stable carbetocin (HSC) for PPH...
4.
Gulmezoglu M, Chinery L, Rushwan S, Ammerdorffer A
Int J MCH AIDS
. 2024 Dec;
13(Suppl 1):S9-S14.
PMID: 39629307
Postpartum hemorrhage (PPH) persists as the leading direct cause of maternal mortality in low- and middle-income countries (LMICs) and is a major global health challenge. Following favorable evidence from pivotal...
5.
Rushwan S, Tufa T, Gulmezoglu M
Int J MCH AIDS
. 2024 Dec;
13(Suppl 1):S4-S8.
PMID: 39629306
Maternal mortality remains one of the primary global health challenges of the 21st century, despite major medical advances in the field. Although solutions are available, inequities determine where mothers die,...
6.
Williams C, Adnet G, Gallos I, Coomarasamy A, Gulmezoglu A, Islam M, et al.
BMJ Glob Health
. 2024 Nov;
9(11).
PMID: 39510550
Introduction: Postpartum haemorrhage (PPH) remains the leading cause of maternal death. Yet there is a lack of clarity around what research is needed to determine what works and how best...
7.
Shankar M, Gulmezoglu A, Vogel J, Goudar S, McDougall A, Somannavar M, et al.
Commun Med (Lond)
. 2024 Oct;
4(1):211.
PMID: 39443672
Systematic under-representation of pregnant women and gender diverse pregnant people in clinical research has prevented them from benefitting fairly from biomedical advances. The resulting lack of pharmacological safety and efficacy...
8.
Bautista K, Lee Y, Higgins C, Procter P, Rushwan S, Baidoo A, et al.
PLOS Glob Public Health
. 2024 Jun;
4(6):e0003181.
PMID: 38900726
Uterotonics are essential in preventing postpartum hemorrhage (PPH), the leading direct cause of maternal death worldwide. However, uterotonics are often substandard in low- and middle-income countries, contributing to poor maternal...
9.
Ammerdorffer A, McDougall A, Tuttle A, Rushwan S, Chinery L, Vogel J, et al.
Lancet Glob Health
. 2024 Jun;
12(7):e1174-e1183.
PMID: 38876763
We developed a comprehensive database of medicines that are used or are being investigated for pre-eclampsia or eclampsia, preterm birth or labour, postpartum haemorrhage, intrauterine growth restriction, and fetal distress...
10.
Shankar M, Hazfiarini A, Zahroh R, Vogel J, McDougall A, Condron P, et al.
PLoS Med
. 2024 May;
21(5):e1004405.
PMID: 38814991
Background: Poor representation of pregnant and lactating women and people in clinical trials has marginalised their health concerns and denied the maternal-fetal/infant dyad benefits of innovation in therapeutic research and...